Core Insights - The main business of the company includes medical software research and development, sales, and technical services, providing comprehensive solutions for the healthcare industry [2] - The company's core products are primarily divided into software and services, which account for 77.33% of revenue, and internet healthcare, which accounts for 12.11% [2] - Since its listing in 2011, the company has achieved a cumulative net profit growth of 98.44%, reaching 0.88 billion yuan in the latest fiscal year 2024 [2] Revenue Analysis - In 2020, the company achieved a revenue of 2.267 billion yuan, which increased to 2.782 billion yuan in 2024, although a decline was noted in 2024 [3] Profit Analysis - The company's net profit attributable to shareholders was 491 million yuan in 2020, dropping to 88 million yuan in 2024, indicating significant volatility and an overall downward trend in profit levels [4] Market Performance - Since its IPO, the company's market value has increased by 9.02 times, demonstrating strong growth potential [6] - The peak market value reached 58.552 billion yuan on July 10, 2020, with the stock price rising to 27.44 yuan, but by August 15, the market value had decreased to 23.035 billion yuan, representing a loss of 35.517 billion yuan or 60.66% from its peak [6]

Group 1 - The core viewpoint of the news is that Weining Health's stock performance shows a significant increase in PE ratio, reaching a new low in 93 days, while the company faces declining revenue and profit [1] - As of August 7, Weining Health's closing price was 11.26 yuan, with a PE ratio of 325.42, which is substantially higher than the industry average of 126.43 and the median of 87.93 [1][2] - The company's total market capitalization is 24.915 billion yuan, ranking it 175th in the software development industry based on PE ratio [1] Group 2 - In terms of capital flow, on August 7, Weining Health experienced a net inflow of 66.5256 million yuan, but over the past five days, there was a total outflow of 23.6179 million yuan [1] - The latest quarterly report for Q1 2025 indicates that Weining Health achieved a revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18% year-on-year, with a gross margin of 34.46% [1]

Core Viewpoint - The stock price of Weining Health closed at 11.23 yuan, marking a 3.31% increase, with a rolling PE ratio of 324.55, the lowest in 89 days, and a total market capitalization of 24.848 billion yuan [1] Company Summary - Weining Health Technology Group Co., Ltd. focuses on integrated solutions in the healthcare sector, providing research, sales, and technical services, primarily in software and services, hardware sales, and internet healthcare [1] - As of July 31, 2025, the number of shareholders is 121,522, a decrease of 2,326 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] Financial Performance - In the first quarter of 2025, Weining Health reported revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18%, with a gross profit margin of 34.46% [1] Industry Comparison - The average PE ratio for the software development industry is 123.47, with a median of 85.64, placing Weining Health at the 177th position in the industry ranking [1][2] - The static PE ratio for Weining Health is 282.71, while the industry average is 132.65 [2]

Core Viewpoint - The company, Weining Health, is experiencing a significant decline in its financial performance, with a high price-to-earnings (PE) ratio compared to industry averages, indicating potential overvaluation in the context of its recent earnings report [1][2]. Company Summary - Weining Health's stock closed at 10.46 yuan, down 2.15%, with a rolling PE ratio of 302.30 times, and a total market capitalization of 23.145 billion yuan [1]. - The company operates in the software development sector, which has an average PE ratio of 125.57 times and a median of 85.99 times, placing Weining Health at the 175th position in the industry ranking [1]. - As of the first quarter of 2025, 13 institutions hold shares in Weining Health, all being funds, with a total holding of 30.8435 million shares valued at 327 million yuan [1]. Financial Performance - In the first quarter of 2025, Weining Health reported a revenue of 345 million yuan, representing a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18% year-on-year, with a gross margin of 34.46% [1].

最新一期业绩显示，2025年一季报，公司实现营业收入3.45亿元，同比-30.24%；净利润528.94万元，同 比-68.18%，销售毛利率34.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)13卫宁健康300.28261.573.88229.90亿行业平均 121.93130.489.25123.77亿行业中值84.3689.164.2358.10亿1理工能科17.9717.421.6448.34亿2思维列控 18.8019.702.24108.05亿3北路智控23.7724.402.0349.10亿4凌志软件29.4347.284.4658.76亿5泽宇智能 29.9328.472.5662.19亿6天玛智控31.7127.352.1192.88亿7中控技术33.9733.203.56370.87亿8熵基科技 35.0935.691.9365.33亿9博思软件38.3837.474.37113.28亿10远光软件40.5540.583.23118.88亿11柏楚电子 41.7344.666.87394.20亿12云星宇42.0241.633.1848.33亿 来源：金融界 7月22日， ...

Core Viewpoint - The company, Weining Health, is experiencing a significant decline in its financial performance, with a high price-to-earnings (PE) ratio compared to industry averages, indicating potential overvaluation in the market [1][2]. Company Summary - Weining Health's stock closed at 10.25 yuan, down 1.54%, with a rolling PE ratio of 296.23 times, and a total market capitalization of 22.68 billion yuan [1]. - The company operates in the software development industry, which has an average PE ratio of 119.15 times and a median of 86.84 times, placing Weining Health at the 176th position in the industry ranking [1][2]. - The main business of Weining Health includes research and development, sales, and technical services, focusing on integrated healthcare information solutions [1]. Financial Performance - In the first quarter of 2025, Weining Health reported a revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.29 million yuan, down 68.18% compared to the previous year, with a gross profit margin of 34.46% [1]. - On July 14, the company experienced a net outflow of 38.70 million yuan in principal funds, although there was an overall inflow of 103.45 million yuan over the past five days [1].

Core Viewpoint - The company, Weining Health, has a high rolling price-to-earnings (PE) ratio of 289.29, significantly above the industry average of 120.22, indicating potential overvaluation in the software development sector [1][2]. Group 1: Company Performance - As of July 8, Weining Health's stock closed at 10.01 yuan, with a 1.32% increase [1]. - The company reported a revenue of 345 million yuan for Q1 2025, reflecting a year-on-year decrease of 30.24% [1]. - The net profit for the same period was 5.29 million yuan, down 68.18% year-on-year, with a gross margin of 34.46% [1]. Group 2: Shareholding and Market Position - As of Q1 2025, 21 institutions held shares in Weining Health, including 19 funds, with a total holding of approximately 29.25 million shares valued at 3.16 billion yuan [1]. - The total market capitalization of Weining Health is 22.149 billion yuan [1][2]. Group 3: Industry Comparison - The average PE ratio for the software development industry is 120.22, with a median of 86.10, positioning Weining Health at the 175th rank within the industry [1][2]. - The industry average price-to-book (PB) ratio is 9.05, while the median is 4.00, indicating a higher valuation compared to peers [2].

序号股票简称PE(TTM)PE(静)市净率总市值(元)13卫宁健康256.63223.543.32196.48亿行业平均 113.34128.948.15113.18亿行业中值80.9583.203.7854.27亿1理工能科16.5916.081.5244.63亿2思维列控 16.6617.471.9895.78亿3北路智控21.9422.531.8745.33亿4凌志软件27.0743.484.1054.04亿5泽宇智能 28.3927.002.4358.97亿6天玛智控29.0425.041.9385.04亿7中控技术31.0530.353.25339.01亿8熵基科技 31.9332.481.7659.45亿9博思软件35.3534.514.02104.33亿10能科科技36.6935.402.3067.88亿11远光软件 36.9837.012.94108.40亿12普联软件38.2232.793.1439.76亿 来源：金融界 6月23日，卫宁健康今日收盘8.88元，上涨1.72%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到256.63倍，总市值196.48亿元。 从行业市盈率排 ...

Group 1 - The core viewpoint of the news is that Weining Health's stock performance shows a significant decline in earnings and a high price-to-earnings (PE) ratio compared to industry averages [1] - As of June 5, Weining Health's closing price was 9.73 yuan, with a PE ratio of 281.19, marking a new low in 11 days and a total market capitalization of 21.529 billion yuan [1] - The average PE ratio for the software development industry is 113.54, with a median of 80.64, placing Weining Health at the 176th position in the industry ranking [1] Group 2 - As of May 30, 2025, Weining Health had 117,272 shareholders, a decrease of 2,683 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1] - The company's main business includes research and development, sales, and technical services, focusing on integrated healthcare information solutions [1] - In the first quarter of 2025, Weining Health reported a revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18%, with a gross margin of 34.46% [1]

Group 1 - The core viewpoint of the news is that Weining Health's stock performance is under pressure, with a significant decline in both revenue and net profit in the latest quarterly report [1] - As of May 28, Weining Health's closing price was 9.41 yuan, down 1.67%, with a rolling PE ratio of 271.94 times, and a total market value of 20.821 billion yuan [1] - In terms of industry comparison, the average PE ratio for the software development industry is 108.85 times, with a median of 76.53 times, placing Weining Health at the 177th position [1] Group 2 - The latest quarterly report for Q1 2025 shows that Weining Health achieved operating revenue of 345 million yuan, a year-on-year decrease of 30.24%, and a net profit of 5.2894 million yuan, down 68.18% year-on-year, with a gross margin of 34.46% [1] - The company has experienced a net outflow of main funds amounting to 41.3338 million yuan on May 28, with a total outflow of 97.9302 million yuan over the past five days [1] - The company's main business includes research and development, sales, and technical services, providing integrated solutions for healthcare information technology [1]